Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. - Wikidata - wikimedia - TriplyDB

Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.

Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.

http://www.wikidata.org/entity/Q36763844

about

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients Variants in TRIM44 Cause Aniridia by Impairing PAX6 Expression A new method to assay protease based on amyloid misfolding: application to prostate cancer diagnosis using a panel of proteases biomarkers Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy.Emerging role of sirtuins on tumorigenesis: possible link between aging and cancer A panel of overexpressed proteins for prognosis in esophageal squamous cell carcinoma.Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.Surgical treatments for esophageal cancers.The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma.When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?Research advances in esophageal diseases: bench to bedside TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma.MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.A novel molecular and clinical staging model to predict survival for patients with esophageal squamous cell carcinoma.The '-omics' revolution and oesophageal adenocarcinoma.Novel diagnostic and prognostic biomarkers in esophageal cancer.Histopathology in barrett esophagus and barrett esophagus-related dysplasia.Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery.Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, "selectivity pocket" and NAD+-binding site.Prognostic value of an immunohistochemical signature in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy.Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling.Optimizing sharing of hospital biobank samples.CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy.Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer.Absence or low IGF-1R-expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection.Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis.Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

P2860

Q28085367-D99B77A5-5D75-4828-895F-3E357B18863E Q28088453-BAD0A6AF-B9C2-40B4-AFFC-9C55CDCB1109 Q28116169-AEB9C3F0-DA0C-4FEF-8272-37787CEBFBE3 Q30437769-24F86EEB-2D74-4281-AAD8-06575235150F Q33958974-CC301357-810F-4BD4-90C5-8FF39D2FA04B Q34049423-5DB06F69-BC8A-4299-B1B7-8C002412A914 Q34388422-C9164F26-C969-4E90-B946-BF2E884871D2 Q35218771-F47E57AA-B33D-4BC0-9BE0-CD78601BBBEC Q35256054-CE449C18-C9E5-4675-ABAC-8E1AA72A741A Q36075141-31F92381-9970-41EB-BC04-04684E7F861E Q36442945-695FFA1C-A853-439D-9702-451818C644C9 Q37215328-6D5085DB-1736-40C1-8C85-2D8775BC6B2A Q37327518-EB6B4D3F-90F6-4866-A53D-3FEEE12E592B Q37488137-E7216411-F9F0-4774-9114-E10E1CFD5201 Q37604087-28A6DABC-3381-4FBD-BFC4-73A6C41FEBE6 Q37665380-8F65E39A-1E47-45C5-9920-D6533A8C519D Q38132057-599B5BEA-0B50-4F4E-B825-80F15AF1FDFA Q38149245-A17F063A-714C-441E-BA3B-DE8D66406001 Q38191222-C706DC97-22DE-493B-91C3-1B9818B1DF68 Q38686553-38402F69-457E-44B3-B6F5-22197B30E93D Q38700230-19720EDE-9F50-4352-A858-A44A65C3810F Q40781429-085FAE68-963F-41DD-835D-120CEDD86670 Q42174323-8EC2B7C7-3408-4E6B-8C2D-2F5D24775255 Q49564870-9C6C611A-3421-46EB-8C75-AA092BF7EB97 Q49989661-2E8214E4-F453-4C29-B8BD-DA1B344D4481 Q50885893-EECA69CB-759A-46B5-8EF6-84C02C30081F Q51541828-D200A935-C24C-486F-94B4-59DFEFA8FD02 Q52725075-B6EC518D-767E-4915-B6D3-4C7CE837227E Q52936444-E642E363-2B45-4DEB-A3F6-0B83AE55CF39 Q54342465-9BE8ED1D-0C8B-4B19-BADE-D8B56385B6E9 Q55435916-031B764C-FD39-4382-A6AA-5A74C4A088D6 Q58697077-0C2B2A05-DE95-45CE-B228-AC85C0ACF848 Q58763391-B5F19B18-4D6E-47A5-B4F4-59E57AE8D010

P2860

Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma.

http://www.wikidata.org/entity/Q36763844

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@ast

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@en

type

label

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@ast

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@en

prefLabel

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@ast

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@en

P1433

Q36763844-A29B0F11-19CE-4C6C-974C-BBAC3D6B57ED

P1476

Q36763844-54D5839E-5E8D-4904-B022-913668E3F6A4

P2093

Q36763844-03391468-5788-41F4-852F-5F004070FD94

Q36763844-0694AD16-E1DA-4A7F-A312-8BCFAF0DFAE0

Q36763844-0799C85D-4A02-435D-8DDD-DE76B04D8E7B

Q36763844-0FB67C86-677E-4BC3-8106-86DEE93A9E5D

Q36763844-29EEC452-A783-4EE6-92B4-AD5619C26F1B

Q36763844-3937243C-7EA9-4B41-B1E2-20F742DF568E

Q36763844-4A128918-5622-43A9-9D94-ECB031B22141

Q36763844-577F985B-AB68-483E-BB46-A6837036F11C

Q36763844-85C82EF7-0A01-4003-B921-539112585E51

Q36763844-95219C44-B716-44CC-8C08-916E4A76788E

P2860

Q36763844-077F29B1-E7D6-4748-8766-F5F70059ED55

Q36763844-11DC7830-FF83-425A-981F-BC329BCB5ACF

Q36763844-164DCB39-A7CA-4E84-87EF-76F196111688

Q36763844-1BBA83E4-12C1-4099-992A-35DA7B4E5EAB

Q36763844-22729CC6-7DE8-4BB2-8D67-4947999B54DF

Q36763844-265CC2A8-344C-440E-950A-1505BD4EC554

Q36763844-29C150A5-F6D8-4B75-9D57-29F6A29329DA

Q36763844-29F27FEA-AAEA-4A10-8AD6-B7EC1CB2C42D

Q36763844-2BE2FC8F-60AE-4038-AB83-30A8500B4748

Q36763844-3747E55E-6184-4D0B-BC11-1A3E10D88607

P304

Q36763844-E57DC9EA-BF12-4741-902A-EECC9BEA636C

P31

Q36763844-6C6EA511-1B7E-4DCE-A912-49EFA02666CA

P356

Q36763844-A8050031-C9D0-4E3C-BE5C-FB7540F4DA05

P407

Q36763844-895CEE3A-D21D-411D-9002-852E00917B22

P433

Q36763844-0055A8C2-F1B2-45E8-9EB5-EC14D653C7B8

P478

Q36763844-236E4786-BC1F-4014-A595-F2ECEC8B49A3

P577

Q36763844-48884579-2F75-4E9A-99E2-AB72B68B7D86

P698

Q36763844-601689A3-B9A2-40CF-A9EA-243EB4BDA471

P921

Q36763844-6881E5D5-115F-4DF7-84E1-A48584D000B0

Q36763844-F7A247F1-8455-439B-B1FD-9C940D266343

P932

Q36763844-9FFB0CD5-C70A-4B54-BAF1-59A6996574CE

P356

JCO.2012.45.9636

P1433

Journal of Clinical Oncology

P1476

Three-gene immunohistochemical ...... ith esophageal adenocarcinoma.

@en

P2093

Bas P L Wijnhoven

http://www.w3.org/2001/XMLSchema#string

Caryn Ross-Innes

http://www.w3.org/2001/XMLSchema#string

Chin-Ann J Ong

http://www.w3.org/2001/XMLSchema#string

James D Luketich

http://www.w3.org/2001/XMLSchema#string

Joel Shapiro

http://www.w3.org/2001/XMLSchema#string

Jon M Davison

http://www.w3.org/2001/XMLSchema#string

Katharina Biermann

http://www.w3.org/2001/XMLSchema#string

Katie S Nason

http://www.w3.org/2001/XMLSchema#string

Laura K E Schulz

http://www.w3.org/2001/XMLSchema#string

Maria O'Donovan

http://www.w3.org/2001/XMLSchema#string

P2860

SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity

TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis

Cancer statistics, 2012

Cell cycle kinases as therapeutic targets for cancer

Clinical application of the 70-gene profile: the MINDACT trial

Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome.

Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.

Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

P304

1576-1582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.45.9636

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23509313

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3625712

http://www.w3.org/2001/XMLSchema#string